CJC-1295 with DAC

Vialdyne primary owner

Overview

CJC-1295 with DAC is the long-acting member of the Modified GRF 1-29 family. The structural difference is a maleimido-propionyl group at Lys30 that reacts covalently with Cys34 of human serum albumin in vivo, the Drug Affinity Complex (DAC) mechanism that gives the SKU its name. The resulting peptide-albumin conjugate circulates with kinetics close to albumin itself, stretching plasma half-life from roughly 30 minutes (no-DAC) to about 6-8 days and supporting once-weekly dosing in both compounding and research contexts. Vialdyne releases CJC-1295 with DAC as the lyophilised acetate against a ≥99.0% main-peak HPLC specification. The DAC variant carries a more demanding analytical burden than the no-DAC form: the maleimido group has to remain intact at the labelled position to retain in vivo albumin-binding activity, and a partially hydrolysed maleimide passes the standard HPLC purity gate at near-identical retention time but is pharmacokinetically inactive. The standard release packet covers peak-integration RP-HPLC plus ESI-MS at the modified mass; an intact-maleimide reactivity assay using a reference thiol target (typically cysteine or N-acetyl-cysteine) is offered as a documented add-on and is available when required by an agreed pharmacy qualification or stability protocol. The DAC PK profile fits sustained-elevation GH preparations and weekly-dosing compounding workflows; for pulse-pharmacology contexts the no-DAC CJC-1295 SKU is the appropriate alternative.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS

863288-34-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 5 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 5.8-8.1 days

MOQ

On request

Lead time

10–18 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Certificate of Analysis

Representative COA previews for CJC-1295 with DAC; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

CJC-1295 with DAC

VD260428-CD051 · 99.23%

VerifiedRequest full COA →

CJC-1295 with DAC

VD260428-CD5052 · 99.17%

Regulatory note

Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
4. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650.

Frequently asked questions